These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 31428326)
41. Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia. Cies JJ; Jain J; Kuti JL Pediatr Blood Cancer; 2015 Mar; 62(3):477-82. PubMed ID: 25328131 [TBL] [Abstract][Full Text] [Related]
42. Piperacillin/tazobactam-induced immune-mediated thrombocytopenia in the intensive care unit. Boyce K; Brar H; Stabler SN J Clin Pharm Ther; 2016 Dec; 41(6):730-732. PubMed ID: 27670947 [TBL] [Abstract][Full Text] [Related]
43. Urinary tract infection by Jiménez-Guerra G; Heras-Cañas V; Gutiérrez-Soto M; Del Pilar Aznarte-Padial M; Expósito-Ruiz M; Navarro-Marí JM; Gutiérrez-Fernández J J Med Microbiol; 2018 Jun; 67(6):790-797. PubMed ID: 29693543 [No Abstract] [Full Text] [Related]
44. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients? McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905 [TBL] [Abstract][Full Text] [Related]
45. [Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia]. Pacheco-Rosas DO; Peregrino-Bejarano L; López-Aguilar JE; Juan-Shum L; Miranda-Novales MG Rev Med Inst Mex Seguro Soc; 2019 Jul; 57(2):65-73. PubMed ID: 31617992 [TBL] [Abstract][Full Text] [Related]
46. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients. Hamidah A; Rizal AM; Nordiah AJ; Jamal R Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765 [TBL] [Abstract][Full Text] [Related]
47. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T; Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406 [TBL] [Abstract][Full Text] [Related]
48. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Peralta FG; Sánchez MB; Roíz MP; Pena MA; Tejero MA; Arjona R Clin Infect Dis; 2003 Dec; 37(11):1568-72. PubMed ID: 14614681 [TBL] [Abstract][Full Text] [Related]
49. Thrombocytosis under ciprofloxacin and tazobactam/piperacillin. Finsterer J; Kotzailias N Platelets; 2003 Aug; 14(5):329-31. PubMed ID: 12944250 [TBL] [Abstract][Full Text] [Related]
50. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections. Young M; Plosker GL Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679 [TBL] [Abstract][Full Text] [Related]
51. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial. Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F; Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117 [TBL] [Abstract][Full Text] [Related]
52. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Johnson DM; Biedenbach DJ; Jones RN Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629 [TBL] [Abstract][Full Text] [Related]
53. Tazobactam and piperacillin-induced thrombocytopenia: A case report. Chen H; Fan Z; Guo F; Yang Y; Li J; Zhang J; Wang Y; LE J; Wang Z; Zhu J Exp Ther Med; 2016 Apr; 11(4):1223-1226. PubMed ID: 27073426 [TBL] [Abstract][Full Text] [Related]
54. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Corapcioglu F; Sarper N; Zengin E Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534 [TBL] [Abstract][Full Text] [Related]
55. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteraemia. Wise R J Antimicrob Chemother; 1993 Jan; 31 Suppl A():97-104. PubMed ID: 8383659 [TBL] [Abstract][Full Text] [Related]
56. Piperacillin/tazobactam-induced neurotoxicity in a hemodialysis patient: a case report. Neves PD; Freitas FM; Kojima CA; Carmello BL; Bazan R; Barretti P; Martin LC Hemodial Int; 2015 Jan; 19(1):143-5. PubMed ID: 25098503 [TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. Kauf TL; Prabhu VS; Medic G; Borse RH; Miller B; Gaultney J; Sen SS; Basu A BMC Infect Dis; 2017 Apr; 17(1):314. PubMed ID: 28454524 [TBL] [Abstract][Full Text] [Related]